Trastuzumab deruxtecan

Active substance

Trastuzumab deruxtecan


Oncology and Hematology

Reason of inclusion

Indication extension

Main indication

Stomach cancer

Extended indication
Treatment of ER2-overexpressing advanced gastric or gastroesophageal junction adenocarcinoma patients who have progressed on two prior treatment regimens


Proprietary name



Daiichi Sankyo

Mechanism of action

Antibody-drug conjugate

Route of administration


Therapeutical formulation

Injection / infusion solution

Budgetting framework

Intermural (MSZ)


Registration route

Centralised (EMA)

Submission date

October 2020

Expected Registration


Orphan drug


Registration phase

Registration application pending

Additional comments
De fabrikant verwacht registratie in 2022.

Therapeutic value

Therapeutic value

No judgement


Op dit moment loopt de DESTINY-Gastric02 studie nog.

Duration of treatment

Not found

Frequency of administration

1 times every 3 weeks

Dosage per administration


Expected patient volume per year

Patient volume

< 78

Market share is generally not included unless otherwise stated.

IKNL; expertopinie; Record rivoceranib
Additional comments
Ongeveer 70 patiënten worden behandeld in de tweede lijn voor gemetastaseerd adenocarcinoom van de maag of gastro-oesofageale overgang. Het aantal patiënten met een slokdarmcarcinoom die in de tweede lijn worden behandeld bedraagt ongeveer 60. In totaal zijn dit dus 130 patiënten. De inschatting is dat hiervan maximaal 60% een derdelijns behandeling krijgt (78 patiënten).

Expected cost per patient per year

Additional comments
Op basis van de Amerikaanse verwachte prijs: $13,300 per maand.

Potential total cost per year

There is currently nothing known about the possible total cost.

Off label use

There is currently nothing known about off label use.

Indication extension

There is currently nothing known about indication extensions.

Other information

There is currently no futher information available.